| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083118 | Drug Discovery Today: Therapeutic Strategies | 2006 | 6 Pages |
Abstract
In a recent study in which Crohn's disease patients were treated with an antibody targeting IL-12p40, 75% of patients exhibited a significant clinical response. The antibody in question blocks two related cytokines, IL-12 and IL-23. This encouraging clinical result prompts us to more fully understand the role of these cytokines and their individual contributions to the inflammatory pathways that underlie the disease.
Section editor:Martin Braddock – AstraZeneca R&D Charnwood, Loughborough, UK
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Geertruida M. Veldman,